Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViraTherapeutics GMBH

www.viratherapeutics.com

Latest From ViraTherapeutics GMBH

Boehringer Ingelheim Is Getting Bets In Early In IO Space

The head of the German family-owned firm's venture fund tells Scrip that investing very early in promising start-ups gives Boehringer Ingelheim "a little bit of a head start" on rival pharma companies in identifying technologies that could translate into therapies five years down the line .

Financing M & A

Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy

Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.

ImmunoOncology M & A

Transgene Hopes To Finally Catch The Wave In Virus Based Immunotherapies

Transgene's CEO discusses its immunotherapy pipeline, coming catalysts, and why the French biotech may soon be swept up by growing interest in oncolytic viruses.

Clinical Trials Companies

Boehringer's Expanded Venture Fund: Innovation First, Returns Second

Boehringer Ingelheim more than doubled its venture fund from €100m to €250m, giving BI more access to early innovation via new capital, two new investment managers and a West Coast presence.

Business Strategies Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • ViraTherapeutics GMBH
  • Senior Management
  • Heinz Schwer, PhD, CEO
    Lisa Egerer, PhD, COO
    Dethardt Muller, PhD, Head of CMC
    Patrik Erlmann, PhD, Head of R&D
    Cedric Cheminay, PhD, Proj Manager, Preclinical Dev, Deputy Head R&D
  • Contact Info
  • ViraTherapeutics GMBH
    Phone: 512 272061
    Exglasse 20a
    Innsbruck, 6020
    Austria
Advertisement
Advertisement
UsernamePublicRestriction

Register